Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients

被引：0
|
作者：
Frigault, Matthew [1 ]
Rosenblatt, Jacalyn [2 ]
Dhakal, Binod [3 ]
Raje, Noopur [4 ]
Cook, Daniella [1 ]
Gaballa, Mahmoud [5 ]
Emmanuel-Alejandro, Estelle [2 ]
Nissen, Danielle [3 ]
Banerjee, Kamalika [6 ]
Rotte, Anand [6 ]
Heery, Christopher [6 ]
Avigan, David [2 ]
Jakubowiak, Andrzej [7 ]
Bishop, Michael [7 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Arcellx Inc, Redwood City, CA USA
[7] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MM; multiple myeloma; BCMA; plasma cell; anitocabtagene autoleucel;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-364
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [31] Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Hiroshi Handa
    Takaaki Chou
    Kenichi Ishizawa
    Takatoshi Takubo
    Yoichi Kase
    International Journal of Hematology, 2017, 105 : 445 - 452
  • [32] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [33] Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
    Mateos, Maria-Victoria
    Engelhardt, Monika
    Leleu, Xavier
    Mesa, Mercedes Gironella
    Cavo, Michele
    Dimopoulos, Meletios
    Bianco, Martina
    Merlo, Giovanni Marino
    Porte, Charles la
    Richardson, Paul G.
    Moreau, Philippe
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 242 - 252
  • [34] Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
    Crusoe, Edvan de Queiroz
    Fernandes Pimenta, Flavia Cristina
    Maiolino, Angelo
    de Castro, Nelson Siqueira
    Pei, Huiling
    Trufelli, Damila
    Fernandez, Mariana
    Herriot, Luciana Barreto
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (04) : 417 - 423
  • [35] Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
    Jagannath, Sundar
    Barlogie, Bart
    Berenson, James R.
    Siegel, David S.
    Irwin, David
    Richardson, Paul G.
    Niesvizky, Ruben
    Alexanian, Raymond
    Limentani, Steven A.
    Alsina, Melissa
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (04) : 537 - 540
  • [36] Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
    Zhao, Wan-Hong
    Wang, Bai-Yan
    Chen, Li-Juan
    Fu, Wei-Jun
    Xu, Jie
    Liu, Jie
    Jin, Shi-Wei
    Chen, Yin-Xia
    Cao, Xing-Mei
    Yang, Yun
    Zhang, Yi-Lin
    Wang, Fang-Xia
    Zhang, Peng-Yu
    Lei, Bo
    Gu, Liu-Fang
    Wang, Jian-Li
    Zhang, Hui
    Bai, Ju
    Xu, Yan
    Zhu, Han
    Du, Juan
    Jiang, Hua
    Fan, Xiao-Hu
    Li, Jian-Yong
    Hou, Jian
    Chen, Zhu
    Zhang, Wang-Gang
    Mi, Jian-Qing
    Chen, Sai-Juan
    He, Ai-Li
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [37] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    LEUKEMIA RESEARCH, 2019, 83
  • [38] Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study
    Andreozzi, Fabio
    Dragani, Matteo
    Quivoron, Cyril
    Le Bras, Fabien
    Assi, Tarek
    Danu, Alina
    Belhadj, Karim
    Lazarovici, Julien
    Cotteret, Sophie
    Bernard, Olivier A.
    Ribrag, Vincent
    Michot, Jean-Marie
    CANCERS, 2023, 15 (05)
  • [39] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida
    Kenshi Suzuki
    Shigeru Kusumoto
    Masaki Ri
    Nobuhiro Tsukada
    Yu Abe
    Masayuki Aoki
    Mitsuo Inagaki
    International Journal of Hematology, 2017, 106 : 541 - 551
  • [40] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Iida, Shinsuke
    Suzuki, Kenshi
    Kusumoto, Shigeru
    Ri, Masaki
    Tsukada, Nobuhiro
    Abe, Yu
    Aoki, Masayuki
    Inagaki, Mitsuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 541 - 551
12345